CXCL2/CXCL8 Promote Intervertebral Disc Degeneration

NCT ID: NCT05976516

Last Updated: 2023-08-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-01

Study Completion Date

2024-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is very common among subjects under 30 years old. In addition to age, there are other factors, such as excessive or uneven mechanical load, obesity, genetics, nutrition, trauma and gender. In addition, it is not clear whether the heavy physical load associated with occupation is an important risk factor for IDD. Some studies have found that IDD is more common among athletes than the general population. Due to the complexity and multifactorial nature of IDD, its pathogenesis and risk factors are still unclear, which seriously hinders the rational stratification of LBP patients and limits the development of personalized treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cytokine Intervertebral Disc, Degenerative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pirffmann 2 grade

CXCL2/CXCL8

Intervention Type DIAGNOSTIC_TEST

Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

pirffmann 3 grade

CXCL2/CXCL8

Intervention Type DIAGNOSTIC_TEST

Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

pirffmann 4 grade

CXCL2/CXCL8

Intervention Type DIAGNOSTIC_TEST

Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

pirffmann 5 grade

CXCL2/CXCL8

Intervention Type DIAGNOSTIC_TEST

Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CXCL2/CXCL8

Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* It meets the diagnostic criteria of lumbar disc degeneration; No previous history of spinal surgery; Good ability of independent behavior and cooperation in completing research; The patient is aware of this study and has signed the consent form.

Exclusion Criteria

* Patients with spinal tumor, infection, tuberculosis and other diseases; Patients with claustrophobia; Parkinson's syndrome patients; Poor cooperation, Poor image quality; Patients with osteoporosis.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhongda Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

pengfei, xue

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongda Hospital

Nanjing, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lei liu, Dr

Role: primary

18934544893

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20220224016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.